Veracyte Announces Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall St set for muted open as tech wobble persists; Tesla gains
- Oil heads for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Vertiv shares fall on analyst downgrades and options bets
- European stocks rise, dollar set for weekly loss after yields drop
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Veracyte (VCYT) to See Possible Medicare Payment Cut; Leerink Partners Cuts Price Target to $11
November 6, 2015 8:24 AM ESTLeerink Partners maintained an Outperform rating on Veracyte, Inc (NASDAQ: VCYT), and cut the price target to $11.00 (from $13.00), following the company's 3Q earnings report. VCYT reported Q3 revenue of $12.3M, slightly below the Streets $12.6M. VCYT noted some additional wins with Blues plans in the... More
Sanofi (SNY) Will Outline Long-Term Roadmap; Sees Sales CAGR at 3% - 4% from 2015 -20
November 6, 2015 6:25 AM ESTSanofi (NYSE: SNY) will host an Investor Relations seminar today ('Meet Sanofi Management') at which it will set out its strategic roadmap for the period 2015-2020 and its ambition to become the pre-eminent diversified global healthcare company. Through a process of refocusing and reshaping the organisation and investing in key launches and businesses, Sanofi expects to deliver a sales compound annual growth rate (CAGR) of between +3% and +4%4 over 2015-2020, with a target of mid-single digit... More
Veracyte (VCYT) Tops Q3 EPS by 1c
November 5, 2015 5:28 PM ESTVeracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $12.72 million.
For earnings history and earnings-related data on Veracyte (VCYT) click here.
... More


